Your browser doesn't support javascript.
loading
Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.
Gonzalez-Angulo, Ana M; Lei, Xiudong; Alvarez, Richardo H; Green, Majorie C; Murray, James L; Valero, Vicente; Koenig, Kimberly B; Ibrahim, Nuhad K; Litton, Jennifer K; Nair, Lakshmy; Krishnamurthy, Savitri; Hortobagyi, Gabriel N; Meric-Bernstam, Funda.
Afiliación
  • Gonzalez-Angulo AM; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Lei X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Alvarez RH; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Green MC; Genentech, South San Francisco, CA.
  • Murray JL; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Valero V; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Koenig KB; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Ibrahim NK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Litton JK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Nair L; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Krishnamurthy S; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Hortobagyi GN; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: fmeric@mdanderson.org.
Clin Breast Cancer ; 15(5): 325-31, 2015 Oct.
Article en En | MEDLINE | ID: mdl-25913905
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 / Epotilonas / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: Clin Breast Cancer Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 / Epotilonas / Antineoplásicos Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: Clin Breast Cancer Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article Pais de publicación: Estados Unidos